

Ganoderma lucidum: A Review with Special Emphasis on the Treatment of Various Cancer

Mani Rupeshkumar¹, Upashna Chettri^{1*}, Jaikumar S¹, Rathi Bai M¹ and Padma M Paarakh²

¹Department of Pharmacology, Oxford College of Pharmacy, Bengaluru, India

²Department of Pharmacognosy, Oxford College of Pharmacy, Bengaluru, India

*Corresponding author: Upashna Chettri, Department of Pharmacology, The Oxford College of Pharmacy, Bengaluru, India, Tel: 918050480473; E-mail: upashna.chettri21@gmail.com

Received date: July 01, 2016; Accepted date: July 19, 2016; Published date: July 28, 2016

Copyright: © 2016 Rupeshkumar M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Ganoderma lucidum, commonly referred to as Lingzhi or Reishi, is a basidiomycete rot fungus which has been used for centuries in East Asia for promotion of good health and longevity. The main bioactive components of *G. lucidum* can be broadly grouped into polysaccharides and triterpenes. The anticancer properties of *G. lucidum* have been proved in both *in vitro* and *in vivo* studies using human and murine cell lines. Various pharmacological activities have been reported such as, hepatoprotective, anti-diabetic, anti-hypertensive, cardioprotective, immune modulatory, antioxidant, anticancer, etc. Regardless of polysaccharides and triterpenes have been used for treatment of different types of cancers the mechanism by which they exert their anticancer effect remains undefined.

The aim of this paper is to summarise the treatment of various cancer with respect to various mechanisms that have been suggested for the anticancer properties of polysaccharides and triterpenes extracted from *G. lucidum*.

Keywords: *Ganoderma lucidum*; Basidiomycete; Polysaccharides; Triterpenes; Anticancer properties; Murine

Introduction

Ganoderma lucidum is a basidiomycete white rot fungus [1] that belongs to the family Polyporaceae (or Ganodermataceae) of Aphyllophorales [2]. It is commonly known as “Lingzhi” in Chinese, “Reishi” in Japanese and “Youngzhi” in Korean [3]. Its medicinal values has been documented in the Chinese literature which can be dated back nearly two thousand years to the Shen Nong Materia Medica (102–200AD). It is regarded as a symbol of happiness, good fortune, good health and even immortality in Chinese traditional culture [4].

More than 120 species of *Ganoderma* have been reported in the world out of which 98 species were found in China. However, only two species of *Ganoderma* (Figure 1) i.e., *G. lucidum* (Leyss.ex Fr.) Karst. and *Ganoderma sinense* Zhao, Xu et Zhang, are documented in Chinese Pharmacopoeia (2010) as Lingzhi [5]. The fungus is commonly used in East Asian countries for the promotion of health and longevity and as a remedy for illness. *Ganoderma* is consumed for its medicinal value rather than nutritional value. Lingzhi has been reckoned to extend the life span and to increase youthful vigour and vitality [6].




Figure 1: Raw materials of (A) *Ganoderma lucidum* and (B) *Ganoderma sinense* [5].

Chemistry

Ganoderma contains various bioactive components which are mainly located in the shiny fruiting body, mycelium and spores [7]. It has been indicated that *G. lucidum* might produce as many as ~400 different bioactive compounds [8]. The primary active ingredient of *G. lucidum* is polysaccharides [9]. It also contains secondary metabolites such as triterpenoids [10,11], alkaloids [12], proteins [12], coumarin [13], flavonoid [7], phenols [7], lignocellulose degrading enzymes [1] and nucleosides [14].

Pharmacological Activities

The polysaccharides fraction of *G. lucidum* has been manifested to activate immune effector cells and suppress the growth of several cancer

cells *in vivo* [15]. According to recent studies β -(1 \rightarrow 3) D-glucan of polysaccharide fraction was found to be carcinostatic substance present in *G. lucidum* [16]. The mushroom contains glycans as a large group of polysaccharide. Glycans consists of arabinose, mannose, fucose, galactose, xylose, glucuronic acid and also glucose [17]. The other pharmacological properties of polysaccharides were reported such as, hepatoprotective [18], neuroprotective effect [19], anti-amnesic effect [20], anti-epileptic effect [21], anti-obesity effect [22], anti-depressant [23], anti-microbial [24-26], anticancer effect [27,28] and ant diabetic [29].

Ganoderma yields oxygenated triterpenoids (especially ganoderic acids) which has wide range of biological activities. These include differential effects on the inhibition of eukaryotic DNA polymerases, thromboxane A₂-signaling pathways in human platelets, inhibition of tumor invasion *in vitro* and *in vivo*, cytotoxicity to several cancer cells *in vitro*, anti-human immunodeficiency virus-1 protease activity and regulation of osteoclastogenesis [14]. The other pharmacological properties of triterpenoids were reported such as, antihypertensive [30], antianemia [31], cardioprotective [32,33], antifibrotic effect [34,35], anti-oxidant [36], anti-HIV-1 activity [37] and anticancer [38,39].

In this article, we laid emphasis on the treatment of various cancers with *G. lucidum* as well the bioactive pathways which might be associated with the anticancer activity.

Anticancer Activity and Mechanisms of *G. lucidum*

Effect of *G. lucidum* on human colorectal cancer cells

Zengenni et al. reported that cell viability on HCT-116 cells was reduced by GLP in a time- and dose-dependent manner which in turn induced cell apoptosis. Apoptosis was characterized by morphological changes, DNA fragmentation, mitochondrial membrane potential decrease, S phase population increase, and caspase-3 and -9 activation. GLP-induced apoptosis was further decreased by inhibition of c-Jun N-terminal kinase (JNK) by SP600125. Western blot analysis revealed that GLP influenced the expression of Bax/Bcl-2, caspase-3 and poly (ADP-ribose) polymerase (PARP). It has been reported that activation of mitochondrial and mitogen-activated protein kinase (MAK) pathways proved the apoptosis stimulated by GLP in human colorectal cancer cells [40].

Effect of *G. lucidum* on mouse hepatoma, sarcoma S-180 and reticulocyte sarcoma L-II cells

Xin Liu et al. showed the inhibitory effects of dormant spores, the germinating spores, the sporoderm-broken germinating spores (SBGS) and the lipids extracted from the germinating spores of *G. lucidum* on the growth of mouse hepatoma, sarcoma S-180 and reticulocyte sarcoma L-II cells. The sporoderm-broken spores indicated much higher bioactivities than the whole spores. The bioactivities of the spores were enhanced by germinating the dormant spores. The lipids extracted from germinating spores and the sporoderm-broken germinating spores of *G. lucidum* inhibited three tumors in dose-dependent manner with an inhibition of 80-90% [28].

Effect of *G. lucidum* on Lewis lung carcinoma bearing mice

Shiu-Nan et al. showed the effect of mushroom β -glucans (MBGS) by analyzing size of primary tumor and rate of metastasis in Lewis lung

carcinoma (LLC) bearing mice (C57BL/6). MBGS was derived from solid culture of *Ganoderma lucidum* and was administered orally along with radiation therapy. MBGS enhances NK cell-mediated cytotoxicity in mice without LLC bearing mice. When MBGS is administered in conjugation with radiation therapy it serves as a protective factor for the hair loss and wounds due to the overgrowth of primary tumor in LLC bearing mice. It is also effective in controlling tumor growth and rate of metastasis [41].

Effect of *G. lucidum* on colitis associated carcinogenesis in mice

Daniel et al. demonstrated anticancer and anti-inflammatory activity of triterpene extract isolated from *G. lucidum*. It was reported that mice exposed to PhIP/DSS was treated with *G. lucidum* triterpene (GLT) which suppressed focal hyperplasia, aberrant crypt foci (ACF) formation and tumor formation in mice. Further decreased staining with Ki-67 in colon tissues confirmed the anti-proliferative effect of GLT. PhIP/DSS-induced colon inflammation in mice was proved by shortening of the large intestine and macrophage infiltrations. GLT treatment forbade the shortening of colon length and reduced macrophage infiltration. It also decreased PhIP/DSS-dependent expression of cyclin D1, COX-2, CYP1A2 and CYP3A4 in colon tissues [38].

Effect of *G. lucidum* on human ovarian cancer cells

Shuyan et al. reported that treatment with *G. lucidum* reduced proliferation of human ovarian cancer cells (HOCC). It was accounted that decrease in VEGF expression and increase in Cx43 expression in the cancer cells was followed by inhibition of proliferation. The concentration of *G. lucidum* used was correlated for the extent of immune-reactivity of Cx43 or VEGF in cancer cells. The decreased expression of Cx43 in HOCC abolished the effect of *G. lucidum* on cell proliferation without the change of *G. lucidum*-induced attenuation of VEGF expression. The inhibition of HOCC was brought about by decreasing the expression of VEGF and increasing the expression of Cx43 [39].

Effect of *G. lucidum* on inflammatory breast cancer

Ivette et al. showed the mechanism of *G. lucidum* concentrating on the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Early treatment of Inflammatory breast cancer (IBC SUM-149) with Reishi reduces expression of mTOR, reduced eIF4G level coupled with increased levels of eIF4E bound to 4E-BP as well as consequential protein synthesis reduction. Reishi treated severe combined immunodeficient mice injected with IBC cells for 13 weeks showed reduction in tumor growth and weight by 50%. It also showed reduction in the expression of E-cadherin, mTOR, eIF4G and p70S6K and activity of extracellular regulated kinase (ERK1/2). Thus it is evidenced that Reishi suppresses protein synthesis and tumor growth by affecting survival and proliferative signalling pathways [42].

Effect of *G. lucidum* on LNCaP prostate cancer cells

Ben et al. reported that ethanol and ethyl acetate extracts from *Coprinus comatus* and *G. lucidum* inhibit dihydrotestosterone-induced LNCaP cell viability, suppress levels of secreted prostate-specific antigen in a dose-dependent manner. It also causes a G1 phase arrest in LNCaP. When used in combination *C. comatus* and *G. lucidum* decreased androgen and glucocorticoid receptors

transcriptional activity in breast cancer MDA-kb2 cells. It also suppressed androgen receptor (AR) protein level in LNCaP and MDA-kb2 cells in a dose-dependent manner [43].

Effect of *G. lucidum* on human osteosarcoma MG63 cell line

Sun et al. reported the effect SCGLP1 on human osteosarcoma MG63 cell line. The treatment with SCGLP1 showed inhibitory effect on cell proliferation and cell viability of MG63 cells in a dose-dependent manner. It also caused apoptotic death in MG63 cells through an increase in G0/G1 phase arrest. SCGLP1 induced apoptosis was related with protein expression of pro-apoptotic Bax and Bad, decreased expression of anti-apoptotic Bcl-2 and Bcl-XL, loss of mitochondrial membrane potential, the release of mitochondrial cytochrome C to cytosol, and cleavage of caspase-9, caspase-3, and poly (ADP ribose) polymerase (PARP). Pre-treatment with pan-caspase inhibitor had blocked SCGLP1 induced apoptosis in MG63 cells. Hence it was suggested that SCGLP1 induced apoptosis was related to caspase-3 and caspase-9-dependent apoptotic pathway [44].

Effect of *G. lucidum* on mouse myeloma cancer cell line

Tong et al. reported that morphological changes and apoptosis were observed in J558 cells when treated with *G. lucidum* extract at a dose of 150 µg/mL. But when the dose was increased to 200 and 400 µg/mL there was no significant reduction in cell viability. Necrosis occurred which was characterized by small fragments with uniformly stained red nuclei when the dose was increased to 400 µg/mL. After treatment the viable cells decreased by 45.6% whereas the apoptotic and necrotic cells increased by 16.5 and 29.1% respectively. But there was no changes observed in 3T3 cells. Thus it was confirmed various necrotic and apoptotic changes of cells by scanning electron microscopy and transmission electron microscopy [45].

Effect of *G. lucidum* on microRNA miR-378-mediated tumor cells

Wu et al. reported that miR-378 cells were transfected into tumor cells which acquired aggressive properties of cancer cells. Enhanced cell survival and colony formation was observed due to over expression of miR-378 cells which led to multiple drug resistance. To accelerate the death of miR-378-transfected cells higher concentration of chemotherapeutic agents were required rather than control cells. The active ingredient from *G. lucidum* was purified and isolated as ergosterol peroxide which increased the death of miR-378 cells than GFP cells. Thus from here it was shown that lower concentration of ergosterol peroxide was required to enhance death of miR-378-transfected cells compared to chemotherapeutic agents. Thus it serves as a promising new agent which can overcome the resistance of chemotherapeutic agents in cancer cells [46].

Effect of *G. lucidum* on bladder cancer cells

Lu et al. reported chemotherapeutic activity of *G. lucidum* with the help of *in vitro* human urothelial cell (HUC) model which consisted of HUC-PC cells and MTC-11 cells. *G. lucidum* was used to analyse growth inhibition, actin polymerization status, and impact of actin remodelling on cell migration and adhesion. The growth inhibition was associated with G2/M arrest as shown by cell cycle analysis. In less concentration the extract of *G. lucidum* showed actin polymerization. It leads to inhibition of carcinogen 4-aminobiphenyl induced migration in HUC-PC and MTC-11 cells. The expression of matrix

metalloproteinase-2 and focal adhesion kinase were unchanged which suggests that other mechanism may be involved [47].

Effect of *G. lucidum* on lung cancer patient

Sun et al. reported that plasma-induced suppression of lymphocytes in lung cancer patients can be treated with *G. lucidum* polysaccharides (GI-PS). Various immunosuppressive mediators such as, PGE2, TGF-β, IL-10 and VEGF are released by cancer cells to inhibit the immune response. GI-PS antagonises the immune inhibition to facilitate tumor control in animal model. Hence, with the treatment of GI-PS it was possible to suppress proliferation, CD69 expression, and perforin and granzyme B production in lymphocytes which was activated by Phytohemagglutinin (PHA) in the plasma of lung cancer patients. An observation was made that GI-PS can fully or partially reverse those effects [48].

Effect of *G. lucidum* on gastric cancer cell line

Oliveira et al. reported the inhibition of the growth of a gastric cancer cell line (AGS) by interfering with cellular autophagy and cell cycle. *G. lucidum* extract was found to possess antitumor activity. The phytochemical constituent of the various extract of *G. lucidum* from fruiting body and spores were investigated [49].

Current Scenario and Future perspectives

G. lucidum has been used all over the world for centuries as a source of health food supplements and nutraceuticals. It has various pharmacological benefits, such as, hepatoprotective, antidiabetic, antimicrobial, neuroprotective, antihypertensive, cardioprotective, anti-oxidant, anti-HIV-1 activity, immune-modulating, anticancer, etc. The effectiveness of *G. lucidum* reckons mainly on its chemical constituents, namely, polysaccharides and triterpenes that make up the fruiting body, mycelium or spores.

Polysaccharides have been shown to activate immune effector cells and suppress the growth of several cancer cells *in vivo*, enhance the host's immune response by stimulating the production of macrophages, NK cells and T-lymphocytes, etc. It precludes tumor metastasis by various mechanisms such as inhibition of c-Jun N-terminal kinase (JNK) by SP600125, inhibition of VEGF expression, reduced expression of mTOR, reduced eIF4G level, suppressed androgen receptor (AR) protein level; inhibit immunosuppressive mediators such as, PGE2, TGF-β, IL-10, etc.

Triterpenes have shown to inhibit eukaryotic DNA polymerases, thromboxane A2-signaling pathways in human platelets, inhibition of tumor invasion *in vitro* and *in vivo*, cytotoxicity to several cancer cells *in vitro*, anti-human immunodeficiency virus-1 protease activity and regulation of osteoclastogenesis. It also prevented tumor metastasis by inhibiting the expression of cyclin D1, COX-2, CYP1A2 and CYP3A4, regulating MMP and IL-8, suppressed inflammatory cytokine secretion in macrophage cells, down regulation of cyclin D1, etc.

Recently, anticancer activities of polysaccharides and triterpenoids have received much attention in cancer treatment. Various *in vitro* and *in vivo* studies in human and murine cell lines have been demonstrated for its anticancer activity. However, the mechanism responsible for the anticancer activity of *G. lucidum* on cancer treatment lies inconclusive. The current studies provide new insights for cancer prevention and treatment based on various *in vitro* and *in*

vivo studies. *Ganoderma lucidum* represent a promising approach for the development of novel class of anticancer drugs.

Acknowledgement

The authors are gratefully acknowledging The Oxford College of Pharmacy for providing support and facilities for this review work. The author is also thankful to Dr. Jai Kumar S and Dr. Rupesh for help pertaining to complete this study. Author also thanks all people who helped in this work.

References

1. Guo-Jun Y, Ya-Lin Y, Wen-Hui Y, Wei L, Yan-Xia J, et al. (2015) Proteome Exploration to Provide a Resource for the Investigation of *G. lucidum*. PLoS ONE 10: e0119439.
2. Zhou Q, Yang W, Jun-Fang L, Li-Qiong G (2015) Optimization of Medium pH, Growth Media Compositions and Analysis of Nutritional Components of *G. lucidum* in Submerged Culture Fermentation. EJMP 6: 17-25.
3. Sudheesh NP, Ajith TA, Janardhanan KK (2009) *G. lucidum* (Fr.) P. Karst enhances activities of heart mitochondrial enzymes and respiratory chain complexes in the aged rat. Biogerontology 10: 627-636.
4. Xin-Cun W, Rui-Jiao X, Yi L, Dong-Mei W, Yi-Jian Y (2012) The Species Identity of the Widely Cultivated *Ganoderma*, '*G. lucidum*' (Ling-zhi), in China. PLoS ONE 7.
5. Guang-ping L, Zhao J, Jin-ao D, Yu-ping T, Shao-ping L (2012) Comparison of sterols and fatty acids in two species of *Ganoderma*. Chem Cent J 6: 10.
6. Wachtel-Galor S, Tomlinson B, Benzie IFF (2004) *G. lucidum* ('Lingzhi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 91: 263-269.
7. Kirar V, Mehrotra S, Negi PS, Nandi SP, Misra K (2015) HPTLC fingerprinting, antioxidant potential and antimicrobial efficacy of Indian Himalayan Lingzhi: *G. lucidum*. IJPSR 6: 4259-4268.
8. Yen-Hua H, Hung-Yi W, Keh-Ming W, Tze-Tze L, Ruey-Fen L et al. (2013) Generation and Analysis of the Expressed Sequence Tags from the Mycelium of *G. lucidum*. PLoS ONE 8.
9. Ang R, Meng-Jiao L, Liang S, Da-Shuai M, Ai-Liang J et al. (2013) Profiling and Quantifying Differential Gene Transcription Provide Insights into Ganoderic Acid Biosynthesis in *G. lucidum* in Response to Methyl Jasmonate. PLoS ONE 8.
10. Jian-Ping Y, Jiang-Hai W, Xin Liu (2007) Distribution of free and esterified ergosterols in the medicinal fungus *G. lucidum*. Applied Microbiology and Biotechnology 77: 159-65.
11. Xia Q, Zhang H, Sun X, Zhao H, Lingfang W, et al. (2014) A Comprehensive Review of the Structure Elucidation and Biological Activity of Triterpenoids from *Ganoderma* spp. Molecules 19: 17478-17535.
12. Chien CC, Tsai ML, Chen CC, Chang SJ, Tseng ch (2008) Effects on Tyrosinase Activity by the Extracts of *G. lucidum* and Related Mushrooms. Mycopathologia 166: 117-120.
13. Rathor R, Tulsawani R, Misra K (2014) Hydro-ethanolic extract of *G. lucidum* (hegl) shows anti-inflammatory activity on THP1 cytokines and NF- κ B P65 response. Int J Pharm Sci Res 5: 2337-2348.
14. Guo-Jun Y, Wang M, Huang J, Ya-Lin Y, Yi-Jie C, et al. (2012) Deep Insight into the *G. lucidum* by Comprehensive Analysis of Its Transcriptome. PLoS ONE 7.
15. Gao-Qiang L, Hua-Xi X, Xiao-Ling W, Zhao Y, Yong-Guang Z, et al. (2011) Stimulated Production of Triterpenoids of *G. lucidum* by an Ether Extract from the Medicinal Insect, *Catharsius molossus*, and Identification of the Key Stimulating Active Components. Appl Biochem Biotechnol 165: 87-97.
16. Chow-Chin T, Yew-Keong C, Mohamed S, Mustapha NM, Umar NA (2008) Efficacy of *G. lucidum* on plasma lipids and lipoproteins in rats fed with high cholesterol diet. Nutr Food Sci 38: 229-238.
17. Lemieszek M, Rzeski W (2012) Anticancer properties of polysaccharides isolated from fungi of the Basidiomycetes class. Wspolczesna Onkol 16: 285-289.
18. Sun-Hee J, Sung-woo C, Hyun-Min Y, Kyung-Jeon J, Chun-Ho S, et al. (2014) Hepatoprotective Evaluation of *G. lucidum* Pharmacopuncture: In vivo Studies of Ethanol-induced Acute Liver Injury. J Pharmacopuncture 17: 016-024.
19. Zhang W, Zhang Q, Deng W, Li Y, Xing Z, et al. (2014) Neuroprotective effect of pre-treatment with *G. lucidum* in cerebral ischemia/reperfusion injury in rat hippocampus. Neural Regen Res 9: 1446-1452.
20. Choi YJ, Yang HS, Jo JH, Lee SC, Park TY, et al. (2015) Anti-Amnesic Effect of Fermented *G. lucidum* Water Extracts by Lactic Acid Bacteria on Scopalamine-Induced Memory Impairment in Rats. Prev Nutr Food Sci 20: 126-132.
21. Wang SQ, Li XJ, Qiu HB, Jiang ZM, Simon M, et al. (2014) Anti-Epileptic Effect of *G. lucidum* Polysaccharides by Inhibition of Intracellular Calcium Accumulation and Stimulation of Expression of CaMKII in Epileptic Hippocampal Neurons. PLoS ONE 9: e111295.
22. Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, et al. (2015) *G. lucidum* reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun 6: 7489.
23. Matsuzaki H, Shimizu Y, Iwata N, Kamiuchi H, Suzuki F, et al. (2013) Antidepressant-like effects of a water-soluble extract from the culture medium of *G. lucidum* mycelia in rats. ISCMR 13: 370.
24. Nithya M, Ambikapathy V, Panneerselvam A (2013) Studies on Antimicrobial Potential of Different Strains of *G. lucidum* (Curt.: Fr.) P. Karst. Int J Pharm Sci Rev Res 21: 317-320.
25. Celik GY, Onbasli D, Altinsoy B, Alli H (2014) In vitro Antimicrobial and Antioxidant Properties of *G. lucidum* Extracts Grown in Turkey. EJMP 4: 709-722.
26. Nayak RN, Dixitraj PT, Nayak A, Bhat K (2015) Evaluation of antimicrobial activity of spore powder of *G. lucidum* on clinical isolates of *Prevotellaintermedia*: A pilot study. Contemporary Clinical Dentistry 6: 248-252.
27. Sun LX, Lin ZB, Duan XS, Qi HH, Ning Y, et al. (2014) Suppression of the Production of Transforming Growth Factor b1, Interleukin-10, and Vascular Endothelial Growth Factor in the B16F10 Cells by *G. lucidum* Polysaccharides. J Interferon Cytokine Res 34.
28. Liu X, Yuan JP, Chung CK, Chen XJ (2002) Antitumor activity of the sporoderm-broken germinating spores of *G. lucidum*. Cancer Letters 182: 155-161.
29. Pan D, Zhang D, Wu J, Chen C, Xu Z, et al. (2013) Antidiabetic, Antihyperlipidemic and Antioxidant Activities of a Novel Proteoglycan from *G. lucidum* Fruiting Bodies on db/db Mice and the Possible Mechanism. PLoS ONE 8.
30. Tran HB, Yamamoto A, Matsumoto S, Ito H, Igami K, et al. (2014) Hypotensive Effects and Angiotensin-Converting Enzyme Inhibitory Peptides of Reishi (*G. lucidum*) Auto-Digested Extract. Molecules 19: 13473-13485.
31. Hossain S, Bhowmick S, Islam S, Rozario L, Jahan S, et al. (2015) Oral Administration of *G. lucidum* to Lead-Exposed Rats Protects Erythrocytes against Hemolysis: Implicates to Anti-Anaemia. Evidence-Based Complementary and Alternative Medicine.
32. Tanya Chu TW, Iris Benzie FF, Christopher Lam WK, Benny Fok SP, Kenneth Lee KC, et al. (2012) Study of potential cardioprotective effects of *G. lucidum* (Lingzhi): results of a controlled human intervention trial. BJN 107: 1017-1027.
33. Rajasekaran M, Kalaimagal C (2012) Cardioprotective effect of a medicinal mushroom, *G. lucidum* against Adriamycin induced toxicity. Int J Pharmacol 8: 252-258.
34. Kwon SC, Kim YB (2011) Antifibrotic activity a fermentation filtrate of *G. lucidum*. Lab Anim Res 27: 369-371.

35. Lin WC, Lin WL (2006) Ameliorative effect of *G. lucidum* on carbon tetrachloride-induced liver fibrosis in rats. *World J Gastroenterol* 12: 265-270.
36. Deepalakshmi K, Mirunalini S (2013) Modulatory effect of *G. lucidum* on expression of xenobiotic enzymes, oxidant-antioxidant and hormonal status in 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in rats. *Phco Mag* 9: 167-175.
37. El-Mekkawy S, Meselhy MR, Nakamura N, Tezuka Y, Hattori M, et al. (2012) Anti-HIV-1 and anti-HIV-1-protease substances from *G. lucidum*. *Phytochemistry* 49: 1651-1657.
38. Sliva D, Loganathan J, Jiang J, Jedinak A, Lamb JG, et al. (2012) Mushroom *G. lucidum* Prevents Colitis-Associated Carcinogenesis in Mice. *PLoS ONE* 7.
39. Dai S1, Liu J, Sun X, Wang N (2014) *G. lucidum* inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43. *ISCMR* 14: 434.
40. Liang Z, Yi Y, Guo Y, Rencai Wang R, Hu Q, et al. (2014) Chemical Characterization and Antitumor Activities of Polysaccharide Extracted from *G. lucidum*. *Int J Mol Sci* 15: 9103-9116.
41. Chen SN, Chang CS, Hung MH, Chen S, Wang W, et al. (2014) The Effect of Mushroom Beta-Glucans from Solid Culture of *G. lucidum* on Inhibition of the Primary Tumor Metastasis. *Evidence-Based Complementary and Alternative Medicine*.
42. Suarez-Arroyo IJ, Rosario-Acevedo R, Aguilar-Perez A, Clemente PL, Cubano LA, et al. (2013) Anti-Tumor Effects of *G. lucidum* (Reishi) in Inflammatory Breast Cancer in In vivo and Invitro Models. *PLoS ONE* 8: e57431.
43. Zaidman BZ, Wasser SP, Nevo E, Mahajna J (2008) *Coprinus comatus* and *G. lucidum* interfere with androgen receptor function in LNCaP prostate cancer cells. *Molecular Biology Report* 35:107-117.
44. Sun Z, Huang K, Fu X, Zhou Z, Cui Y, et al. (2014) A chemically sulfated polysaccharide derived from *G. lucidum* induces mitochondrial-mediated apoptosis in human osteosarcoma MG63 cells. *Tumor Biol* 35: 9919-9926.
45. Tong CC, Choong YK, Nor-Aini-B U, Noordin MM, Mohamed S (2009) Cytotoxic activity induced by crude extracts of *G. lucidum* (W. Curt.: Fr.) P. Karst. on mouse myeloma cancer cell-line. *World J Microbiol Biotechnol* 25: 687-695.
46. Wu QP, Xie YZ, Deng Z, Li XM, Yang W, et al. (2012) Ergosterol Peroxide Isolated from *G. lucidum* Abolishes MicroRNA miR-378-Mediated Tumor Cells on Chemoresistance. *PLoS ONE* 7: e44579.
47. Lu QY1, Jin YS, Zhang Q, Zhang Z, Heber D, et al. (2004) *G. lucidum* extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. *Cancer Letters* 216: 9-20.
48. Sun LX, Li WD, Lin ZB, Duan XS, Li XF, et al. (2014) Protection Against Lung Cancer Patient Plasma-Induced Lymphocyte Suppression by *G. lucidum* Polysaccharides. *Cell Physiol Biochem* 33: 289-299.
49. Oliveira M, Reis FS, Sousa D, Tavares C, Lima RT, et al. (2014) A methanolic extract of *G. lucidum* fruiting body inhibits the growth of a gastric cancer cell line and affects cellular autophagy and cell cycle. *Food Funct* 5: 1389-1394.